Drugs / KI-MSC-PL-205
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04447833 | Jun 2020 → Jan 2021 | COVID-19, acute respiratory distress syndrome | Uppsala University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KI-MSC-PL-205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04447833 ↗ |
| Known as | Mesenchymal Stromal Stem Cells | “Mesenchymal Stromal Stem Cells - KI-MSC-PL-205” NCT04447833 ↗ |
| Modality | Cell therapy | “Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).” NCT04447833 ↗ |